Learn More

Treatment with DACOGEN (decitabine)

DACOGEN is a prescription medicine for patients with myelodysplastic syndrome (MDS), including previously treated and untreated MDS and de novo (cause unknown) and secondary (treatment-related) MDS of all French-American- British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.

This site will provide you with information about DACOGEN, how DACOGEN may affect MDS, and what you can expect from treatment with DACOGEN, along with helpful resources.

learn more about Dacogen for the treatment of MDS

INDICATION:

DACOGEN is a prescription medicine indicated for treatment of patients with myelodysplastic syndromes (MDS), including:

Previously treated and untreated MDS
De novo (cause unknown) and secondary (treatment-related) MDS:
  • All French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia)
  • Intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups

IMPORTANT SAFETY INFORMATION:

Treatment with DACOGEN is associated with serious, sometimes fatal, blood disorders including:
  • fewer white blood cells (neutropenia and leukopenia), platelets (thrombocytopenia), and/or red blood cells (anemia)
  • fever associated with low white blood cell counts (febrile neutropenia)
  • bone marrow suppression
  • infections
Your doctor will test and monitor your blood cells before and during treatment with DACOGEN. Your doctor may prescribe medicine to help manage your blood cell counts and/or medicines to prevent or treat infections. Your doctor may need to delay your treatment and/or reduce your dose if you experience certain side effects. Patients should monitor and report any symptoms or fever to their doctor as soon as possible
Harm to a fetus when administered to a pregnant woman: Women of childbearing potential and men with female partners of childbearing potential should use effective contraception and avoid pregnancy while taking DACOGEN
Other common side effects including:
  • feeling tired (fatigue)
  • fever (pyrexia)
  • nausea
  • cough
  • reddish or purplish spots (petechiae)
  • constipation
  • diarrhea
  • high blood sugar (hyperglycemia)
DACOGEN should be used with caution if you have kidney or liver problems

Please see FULL PRESCRIBING INFORMATION